Electropharmacology of flestolol for supraventricular tachycardia without associated structural heart disease
- 1 November 1987
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 60 (13) , 1055-1060
- https://doi.org/10.1016/0002-9149(87)90351-1
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmiasThe American Journal of Cardiology, 1987
- Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmiasThe American Journal of Cardiology, 1986
- Reproducibility of arrhythmia induction with intracardiac electrophysiologic testing: Patients with clinical sustained ventricular tachyarrhythmiasJournal of the American College of Cardiology, 1986
- Clinical electrophysiology of flestolol, a potent ultra short-acting beta blockerAmerican Heart Journal, 1986
- Esmolol: A new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmiasJournal of the American College of Cardiology, 1985
- Cardiovascular Pharmacology of ACC-9089—A Novel, Ultra-Short-Acting, β-Adrenergic Receptor AntagonistJournal of Cardiovascular Pharmacology, 1984
- Nadolol and supraventricular tachycardia: An electrophysiologic studyJournal of the American College of Cardiology, 1983
- Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardiaThe American Journal of Cardiology, 1983
- The electrophysiologic effects of intravenous propranolol in the Wolff-Parkinson-White syndromeAmerican Heart Journal, 1979
- The Effects of Propranolol on Induction of A-V Nodal Reentrant Paroxysmal TachycardiaCirculation, 1974